Vertex Pharmaceuticals Incorporated (VRTX) Yield on Cost (YOC): N/A
The yield on cost (YOC) for Vertex Pharmaceuticals Incorporated (VRTX) is N/A.
VRTX Yield on Cost (YOC) Metrics
YIELD ON COST (YOC)
N/A
Interactive Yield on Cost Calculator
Project custom investment returns for Vertex Pharmaceuticals Incorporated (VRTX) based on your custom cost basis.
Starting Yield
0.46%
Ending YOC
1.45%
Year 15 Dividend
$6.34
Cum. Dividends Recd.
$58.65
| Year | Projected Div. / Share | YoY Dividend Hike | Yield on Cost (YOC) | Total Dividends Recd. |
|---|---|---|---|---|
| Initial | $2.00 | — | 0.46% | $0.00 |
| Year 1 | $2.16 | +8.00% | 0.49% | $2.16 |
| Year 2 | $2.33 | +8.00% | 0.53% | $4.49 |
| Year 3 | $2.52 | +8.00% | 0.58% | $7.01 |
| Year 4 | $2.72 | +8.00% | 0.62% | $9.73 |
| Year 5 | $2.94 | +8.00% | 0.67% | $12.67 |
| Year 6 | $3.17 | +8.00% | 0.73% | $15.85 |
| Year 7 | $3.43 | +8.00% | 0.78% | $19.27 |
| Year 8 | $3.70 | +8.00% | 0.85% | $22.98 |
| Year 9 | $4.00 | +8.00% | 0.91% | $26.97 |
| Year 10 | $4.32 | +8.00% | 0.99% | $31.29 |
| Year 11 | $4.66 | +8.00% | 1.07% | $35.95 |
| Year 12 | $5.04 | +8.00% | 1.15% | $40.99 |
| Year 13 | $5.44 | +8.00% | 1.24% | $46.43 |
| Year 14 | $5.87 | +8.00% | 1.34% | $52.30 |
| Year 15 | $6.34 | +8.00% | 1.45% | $58.65 |
Yield on Cost (YOC) Formula
Formula: Yield on Cost = Annual Dividend / Original Purchase Price × 100
Inputs shown in the projection:
- Original purchase price.
- Annual dividend per share at the starting point.
- Assumed annual dividend growth rate.
- Projected annual dividend divided by original purchase price.
Note: Forward projections assume dividends continue to grow at the designated growth rate. Actual dividend payments are declared by corporate boards and are subject to change.
Vertex Pharmaceuticals Incorporated Yield on Cost (YOC) Formula & Definition
Yield on Cost shows the dividend yield based on your original purchase price. As dividends grow, your YOC increases even if the market yield stays the same.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Reshma Kewalramani